Journal of Enzyme Inhibition and Medicinal Chemistry最新文献_第6页

Unlocking the potential of trifluoromethyl pyrrole derivatives in chronic wounds management: rapid synthesis, structural insights, and potent antimicrobial activity. 释放三氟甲基吡咯衍生物在慢性伤口管理中的潜力：快速合成，结构见解和有效的抗菌活性。

IF 5.6 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-06-11 DOI: 10.1080/14756366.2025.2513406

Rafaela Vrabie, Mariana Pinteala, Cristina M Al-Matarneh, Ioana C Marinas, Alina Nicolescu, Sergiu Shova, Mihaela Silion, Mădălina-Diana Gaboreanu, Mariana C Chifiriuc

{"title":"Unlocking the potential of trifluoromethyl pyrrole derivatives in chronic wounds management: rapid synthesis, structural insights, and potent antimicrobial activity.","authors":"Rafaela Vrabie, Mariana Pinteala, Cristina M Al-Matarneh, Ioana C Marinas, Alina Nicolescu, Sergiu Shova, Mihaela Silion, Mădălina-Diana Gaboreanu, Mariana C Chifiriuc","doi":"10.1080/14756366.2025.2513406","DOIUrl":"10.1080/14756366.2025.2513406","url":null,"abstract":"Using a one-pot, three-component approach, we synthesised 25 dihydropyrrol-2-one and two 5-oxo-2,5-dihydrofuran compounds, each featuring two trifluoromethyl groups. This method emphasises timeliness and cost-effectiveness, crucial in drug development. Structural verification was conducted using NMR, FT-IR, MALDI-MS, single-crystal, and powder XRD. The antibacterial and antifungal activities of these compounds were evaluated on yeasts (Candida sp.) and bacteria, including Gram-positive (Staphylococcus aureus, a significant opportunistic pathogen, being more susceptible than S. epidermidis) and Gram-negative strains. Compounds with o-OH and m'-NO2 groups exhibited superior activity, while those with p-OH and m-OMe groups showed slightly lower but still significant activity. For furan structures, Candida albicans displayed greater sensitivity than C. parapsilosis. Additionally, 13 compounds demonstrated haemolysis below 5%, indicating low toxicity.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2513406"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12160334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hidden targets in dermatology: In vitro and In silico inhibitory effects of common 23 dermatologic drugs on human carbonic anhydrase isoenzymes I and II. 皮肤病学中的隐藏靶点：23种常见皮肤药物对人碳酸酐酶同工酶I和II的体外和体内抑制作用

IF 5.4 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-08-05 DOI: 10.1080/14756366.2025.2540935

İlkay Can, Kübra Çıkrıkcı, Nahit Gençer, Harun Uslu

{"title":"Hidden targets in dermatology: In vitro and In silico inhibitory effects of common 23 dermatologic drugs on human carbonic anhydrase isoenzymes I and II.","authors":"İlkay Can, Kübra Çıkrıkcı, Nahit Gençer, Harun Uslu","doi":"10.1080/14756366.2025.2540935","DOIUrl":"10.1080/14756366.2025.2540935","url":null,"abstract":"In this study, we have aimed to determine the in vitro and in silico effects of 23 frequently used dermatologic drugs on human carbonic anhydrase I (hCA I) and II (hCA II). The inhibitory effects of the drugs on hCA I and hCA II were determined by esterase methods. The most potent inhibitors were isotretinoin for hCA I (Ki= 5.75 µM) and valaciclovir for hCA II (Ki= 5.74 µM). Ketotifen (Ki= 6.98 µM), pantoprazole (Ki= 7.16 µM) and acyclovir (Ki= 7.31 µM) were also potent inhibitors for hCA I. Isotretinoin (Ki= 6.54 µM), brivudine (Ki= 7.44 µM) and fluconazole (Ki= 7.91 µM) were also potent inhibitors for hCA II. Terbinafine hydrochloride was a weak CA inhibitor for both of these isoenzymes (Ki= 20.58 µM for hCA I and 20.32 µM for hCA I). Therefore, the drug, having a weak CA inhibitory activity, may be preferred primarily in patients with a skin disease compared to the other drugs due to important physiological functions of CAs. Molecular docking studies have shown that acitretin and isotretinoin, in particular, will inhibit hCA I at lower concentrations and have higher docking scores. For hCA II, it was shown that Isotretinoin and Ketotifen would inhibit at lower concentrations and have higher placement scores.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2540935"},"PeriodicalIF":5.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12326379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144784410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design, synthesis, and evaluation of novel pinane-based thiazolidione derivatives with anti-glioblastoma activity. 具有抗胶质母细胞瘤活性的新型蒎烷基噻唑酮衍生物的设计、合成和评价。

IF 5.4 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-09-04 DOI: 10.1080/14756366.2025.2553691

Wei Shi, Min Hu, Jiale Han, Lei Wang, Yining Jiang, Hongmei Wu, Wei Liu, Biao Xiong, Yunyun Wang

{"title":"Design, synthesis, and evaluation of novel pinane-based thiazolidione derivatives with anti-glioblastoma activity.","authors":"Wei Shi, Min Hu, Jiale Han, Lei Wang, Yining Jiang, Hongmei Wu, Wei Liu, Biao Xiong, Yunyun Wang","doi":"10.1080/14756366.2025.2553691","DOIUrl":"10.1080/14756366.2025.2553691","url":null,"abstract":"A series of pinane-based thiazolidione derivatives were synthesised, and their anti-proliferative effects were investigated by CCK-8 assay. All these compounds exhibited anti-proliferation activity against three glioblastoma cell lines (U87, T98G, and U251). Compound C5 exhibited the strongest inhibition effect against all three cell lines. Through cellular thermal shift (CETSA) assay and drug affinity responsive target stability (DARTS) assay, compound C5 was demonstrated to directly interact with the CDK2 protein. Additional analyses revealed that C5 inhibited cell migration and arrested the cell cycle in glioblastoma cells while also induced mitochondrial apoptosis and autophagy. Immunoblotting analysis indicated that C5 induced the up-regulation of Bax, cleaved caspase 3, cleaved PARP-1, P62, and LC3B, and the down-regulation of Bcl-2, caspase 3, and PARP-1. Importantly, C5 also demonstrated efficacy in a 3D cell culture model. Together, these results highlight the potential of C5 as a lead compound for the development of novel therapies for glioblastoma.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2553691"},"PeriodicalIF":5.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery of a brain penetrant SGK1 inhibitor using a ligand- and structure-based virtual screening methodology. 使用基于配体和结构的虚拟筛选方法发现脑渗透SGK1抑制剂。

IF 5.4 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-08-29 DOI: 10.1080/14756366.2025.2546591

Enrique Madruga, Cecilia Sanchez-Santos, Ignacio Valenzuela-Martínez, David Ramírez, Carmen Gil, Ana Martínez

{"title":"Discovery of a brain penetrant SGK1 inhibitor using a ligand- and structure-based virtual screening methodology.","authors":"Enrique Madruga, Cecilia Sanchez-Santos, Ignacio Valenzuela-Martínez, David Ramírez, Carmen Gil, Ana Martínez","doi":"10.1080/14756366.2025.2546591","DOIUrl":"10.1080/14756366.2025.2546591","url":null,"abstract":"Serum and glucocorticoid-regulated kinase 1 (SGK1) is an underexplored kinase involved in several neurodegenerative diseases. Although SGK1 inhibitors are not available on the market, the absence of side effects in two SGK1 knockout mouse models supports the development of brain-penetrant SGK1 inhibitors to explore their therapeutic potential. Through a combined ligand- and target-based virtual screening using the ECBL, we identified a small heterocyclic molecule with SGK1 inhibitory activity (IC50 = 0.66 ± 0.25 μM). Molecular dynamics simulations revealed two potential binding modes for the candidate compound, offering valuable insights for the further optimisation of this hit. The compound was predicted to be brain-permeable by both in silico methods and experimental assays. It also demonstrated a neuroprotective profile in a cellular model of Alzheimer's disease (AD) and showed a favourable cardiovascular safety profile. Finally, systems pharmacology analysis identified the FOXO1/FOXO3/CREB1 axis as the principal signalling pathway regulated by SGK1 in the context of AD.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2546591"},"PeriodicalIF":5.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The key enzyme PYCR1 in proline metabolism: a dual driver of cancer progression and fibrotic remodeling. 脯氨酸代谢中的关键酶PYCR1：癌症进展和纤维化重塑的双重驱动。

IF 5.4 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-09-02 DOI: 10.1080/14756366.2025.2545620

Peng Guo, Chenchun Wu, Tong Wang, Yajuan Song, Xiaozi Liu, Xiang Wang, Yuhan Zhu, Binyu Song, Yifu Zhu, Juan Zhang, Lei Guo, Rui Tao, Zhou Yu, Baoqiang Song

{"title":"The key enzyme PYCR1 in proline metabolism: a dual driver of cancer progression and fibrotic remodeling.","authors":"Peng Guo, Chenchun Wu, Tong Wang, Yajuan Song, Xiaozi Liu, Xiang Wang, Yuhan Zhu, Binyu Song, Yifu Zhu, Juan Zhang, Lei Guo, Rui Tao, Zhou Yu, Baoqiang Song","doi":"10.1080/14756366.2025.2545620","DOIUrl":"10.1080/14756366.2025.2545620","url":null,"abstract":"Pyrroline-5-Carboxylate Reductase 1 (PYCR1), a member of the PYCR family, is a key enzyme in the proline biosynthesis pathway. Notably, PYCR1 was originally identified via genetic disease research, linking its mutations to the occurrence of cutis laxa. PYCR1 contributes to the pathogenesis of malignancies and fibrotic diseases via mechanisms involving metabolic reprogramming, Extracellular Matrix (ECM) remodelling, and redox homeostasis maintenance. PYCR1 upregulation has been reported in multiple malignancies including Hepatocellular Carcinoma (HCC), Lung Cancer (LC), Breast Cancer (BC), Bladder Cancer (BlC), and Gastric Cancer (GC), where it has been shown to promote cancer proliferation, migration, and therapy resistance, correlating significantly with advanced cancer stages and poor prognosis. On the other hand, in fibrotic disorders, PYCR1-mediated proline metabolism has been linked to the progression of pulmonary, myocardial, and cutaneous fibroses. Notably, although PYCR1-targeted small-molecule inhibitors have demonstrated therapeutic potential in preclinical studies, their clinical translation is yet to be validated.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2545620"},"PeriodicalIF":5.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery and characterization of novel hematopoietic prostaglandin D synthase inhibitors from traditional Chinese medicine: the bioactive potential of dihydroberberine in treatments of Duchenne muscular dystrophy and inflammation-related diseases. 中药中新型造血前列腺素D合成酶抑制剂的发现和表征：二氢小檗碱治疗杜氏肌营养不良和炎症相关疾病的生物活性潜力

IF 5.4 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-09-17 DOI: 10.1080/14756366.2025.2555624

Cheng-Han Li, Min-Che Tung, Cheng-Kuan Tsai, Tz-Chuen Ju, Tien-Sheng Tseng

{"title":"Discovery and characterization of novel hematopoietic prostaglandin D synthase inhibitors from traditional Chinese medicine: the bioactive potential of dihydroberberine in treatments of Duchenne muscular dystrophy and inflammation-related diseases.","authors":"Cheng-Han Li, Min-Che Tung, Cheng-Kuan Tsai, Tz-Chuen Ju, Tien-Sheng Tseng","doi":"10.1080/14756366.2025.2555624","DOIUrl":"10.1080/14756366.2025.2555624","url":null,"abstract":"Inflammation plays a central role in various diseases, necessitating effective anti-inflammatory agents. Prostaglandin D2 (PGD2), a key mediator synthesised by haematopoietic prostaglandin D synthase (H-PGDS), is linked to allergic and inflammatory conditions. This study employed pharmacophore-based screening to identify inhibitors targeting H-PGDS. The model Phar-A2HR2 identified EMy (IC50 = 88.9 ± 1.1 µM) as a potential inhibitor. Further analysis revealed that its analog EMy-5 (dihydroberberine) demonstrated the most potent inhibitory activity (IC50 = 3.7 ± 1.1 µM) and binding affinity (KD = 3.2 ± 0.74 µM). Molecular dynamics simulations revealed stabilising interactions, including π-π stacking, hydrogen bonding, and hydrophobic contacts, in the H-PGDS-EMy-5 complex. Functional assays confirmed that EMy-5 significantly reduced PGD2 production in KU812 cells. These findings highlight EMy-5 as a promising candidate for the treatment of inflammatory and allergic diseases, including Duchenne muscular dystrophy, demonstrating both potent inhibitory activity and strong binding characteristics.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2555624"},"PeriodicalIF":5.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Farnesiferol C enhances the effects of chemotherapy and ionising radiation in human melanoma cells via targeting topoisomerase II alpha. Farnesiferol C通过靶向拓扑异构酶II α增强化疗和电离辐射对人类黑色素瘤细胞的作用。

IF 5.4 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-09-30 DOI: 10.1080/14756366.2025.2565463

Negin Moosavinejad, Zahra Nasiri Sarvi, Hamid Gholamhosseinian, Mehrdad Iranshahi, Fatemeh B Rassouli

{"title":"Farnesiferol C enhances the effects of chemotherapy and ionising radiation in human melanoma cells via targeting topoisomerase II alpha.","authors":"Negin Moosavinejad, Zahra Nasiri Sarvi, Hamid Gholamhosseinian, Mehrdad Iranshahi, Fatemeh B Rassouli","doi":"10.1080/14756366.2025.2565463","DOIUrl":"10.1080/14756366.2025.2565463","url":null,"abstract":"This study evaluated Farnesiferol C (FC), a natural coumarin, as a potential topoisomerase IIα (TOP2A) inhibitor to enhance chemotherapy and ionising radiation (IR) efficacy in melanoma cells. Key targets were identified, followed by enrichment and gene expression analyses, and molecular docking and dynamics simulations. Upon extraction of FC from Ferula szowitsiana, cell treatment with FC, alone or combined with IR or temozolomide (TMZ), was performed, and viability and apoptosis were assessed. TOP2A emerged as a hub target, showing elevated expression in melanoma and a negative correlation with patient survival. Simulations demonstrated stable binding of FC at the ATP-binding site of TOP2A. Experimental data revealed selective cytotoxicity of FC on A375 melanoma cells (IC50: 76.9 µM, SI: 4.97), sparing normal fibroblasts. Combination treatments with IR or TMZ further increased cytotoxicity and apoptosis. These findings suggest FC as a promising TOP2A inhibitor that potentiates the DNA damage effects of chemoradiotherapy in melanoma.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2565463"},"PeriodicalIF":5.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small molecules targeting the eubacterial β-sliding clamp discovered by combined in silico and in vitro screening approaches. 通过硅内和体外联合筛选方法发现了靶向真菌性β-滑动钳的小分子。

IF 5.6 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-01-03 DOI: 10.1080/14756366.2024.2440861

Alessia Caputo, Gian Marco Elisi, Elisabetta Levati, Giulia Barotti, Sara Sartini, Jerome Wagner, Dominique Y Burnouf, Simone Ottonello, Silvia Rivara, Barbara Montanini

{"title":"Small molecules targeting the eubacterial β-sliding clamp discovered by combined in silico and in vitro screening approaches.","authors":"Alessia Caputo, Gian Marco Elisi, Elisabetta Levati, Giulia Barotti, Sara Sartini, Jerome Wagner, Dominique Y Burnouf, Simone Ottonello, Silvia Rivara, Barbara Montanini","doi":"10.1080/14756366.2024.2440861","DOIUrl":"https://doi.org/10.1080/14756366.2024.2440861","url":null,"abstract":"Antibiotic resistance stands as the foremost post-pandemic threat to public health. The urgent need for new, effective antibacterial treatments is evident. Protein-protein interactions (PPIs), owing to their pivotal role in microbial physiology, emerge as novel and attractive targets. Particularly promising is the α-subunit/β-sliding clamp interaction, crucial for the replicative competence of bacterial DNA polymerase III holoenzyme. Through pharmacophore-based virtual screening, we identified 4,000 candidate small molecule inhibitors targeting the β-clamp binding pocket. Subsequently, these candidates underwent evaluation using the BRET assay in yeast cells. Following this, three hits and 28 analogues were validated via Protein Thermal Shift and competitive ELISA assays. Among them, thiazolo[4,5-d]-pyrimidinedione and benzanilide derivatives exhibited micromolar potency in displacing the β-clamp protein partner and inhibiting DNA replication. This screening campaign unveiled new chemical classes of α/β-clamp PPI disruptors capable of inhibiting DNA polymerase III activity, which lend themselves for further optimisation to improve their antibacterial efficacy.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2440861"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Profiling and cheminformatics bioprospection of curcurbitacin I and momordin Ic from Momordica balsamina on α-amylase and α-glucosidase. 苦瓜α-淀粉酶和α-葡萄糖苷酶活性分析及化学信息学生物展望。

IF 5.6 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-04-29 DOI: 10.1080/14756366.2025.2492706

Viruska Jaichand, Adedayo Ayodeji Lanrewaju, Himansu Baijnath, Saheed Sabiu, Viresh Mohanlall

{"title":"Profiling and cheminformatics bioprospection of curcurbitacin I and momordin Ic from Momordica balsamina on α-amylase and α-glucosidase.","authors":"Viruska Jaichand, Adedayo Ayodeji Lanrewaju, Himansu Baijnath, Saheed Sabiu, Viresh Mohanlall","doi":"10.1080/14756366.2025.2492706","DOIUrl":"https://doi.org/10.1080/14756366.2025.2492706","url":null,"abstract":"Momordica spp. has been traditionally used to manage type 2 diabetes mellitus, but the mechanisms and metabolites remain unclear. This study evaluated the inhibitory potential of Momordica balsamina extracts on α-amylase and α-glucosidase in vitro, identifying cucurbitacin I and momordin Ic via high-performance liquid chromatography-photo diode array, and their inhibitory potential in silico. Ethyl acetate seed extract (14.46 µg/ml) and hexane fruit flesh extract (16.79 µg/ml) exhibited lower IC50 values against α-amylase and α-glucosidase, respectively, compared to acarbose (reference standard). Comparatively, momordin Ic concentrations (36.57-605.98 µg/ml) were higher than cucurbitacin I (17.08-44.34 µg/ml). A 140 ns simulation showed that cucurbitacin I (-63.06 kcal/mol) and momordin Ic (-66.53 kcal/mol) exhibited stronger binding to α-amylase than acarbose (-36.46 kcal/mol), whereas cucurbitacin I (-38.08 kcal/mol) and momordin Ic (-54.87 kcal/mol) displayed weaker binding to α-glucosidase, relative to acarbose (-63.73 kcal/mol). Generally, momordin Ic demonstrated better thermodynamic properties, hence further in vitro and in vivo studies are needed to validate their antidiabetic potential.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2492706"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Activity guided discovery of dual inhibitors of α-glucosidase and β-glucuronidase from the leaves of Millettia pachycarpa Benth. 以活性为导向，从厚木叶中发现α-葡萄糖苷酶和β-葡萄糖苷酶双抑制剂。

IF 5.6 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2025-12-01 Epub Date: 2025-05-15 DOI: 10.1080/14756366.2025.2501041

Yanxi He, Huanran Xu, Shaoqian Tan, Jing Long, Hui Lei, Ling Xiao, Xiaoyi Qi, Mingming Deng, Xia Xiong, Jingcan You, Liangliang Zhu, Muhan Lü, Sicheng Liang

{"title":"Activity guided discovery of dual inhibitors of α-glucosidase and β-glucuronidase from the leaves of Millettia pachycarpa Benth.","authors":"Yanxi He, Huanran Xu, Shaoqian Tan, Jing Long, Hui Lei, Ling Xiao, Xiaoyi Qi, Mingming Deng, Xia Xiong, Jingcan You, Liangliang Zhu, Muhan Lü, Sicheng Liang","doi":"10.1080/14756366.2025.2501041","DOIUrl":"10.1080/14756366.2025.2501041","url":null,"abstract":"Type 2 diabetes mellitus (T2DM) and cancers are two globally prevalent diseases which can increase the incidence of each other. Intestinal α-glucosidase and β-glucuronidase are key targets for glycaemic control and chemotherapy detoxification, respectively. This study first found that the leaf methanol extract of Millettia pachycarpa displayed dual inhibition to the two enzymes. The dually active constituents were then isolated and identified as two prenylated isoflavones of 6,8-diprenylorobol and 6,8-diprenylgenistein. Diprenylorobol exhibits competitive inhibition to both the two enzymes with Ki values of 21.6 μM (α-glucosidase) and 1.41 μM (β-glucuronidase). Diprenylgenistein is an uncompetitive inhibitor of α-glucosidase (Ki = 11.4 μM) but a competitive inhibitor of β-glucuronidase (Ki = 1.69 μM). Molecular docking studies showed that both the two isoflavones tightly bind into the active pockets via various hydrogen bonds and hydrophobic interactions. In summary, the current study identifies two promising dual inhibitors of α-glucosidase and β-glucuronidase from the leaves of Millettia pachycarpa.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"40 1","pages":"2501041"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0